ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02639520
Recruitment Status : Completed
First Posted : December 24, 2015
Last Update Posted : July 28, 2017
Sponsor:
Information provided by (Responsible Party):
Bionorica SE

Brief Summary:
To demonstrate non-inferiority of a non-antibiotic therapy with CLR versus an antibiotic treatment with fosfomycin trometamol in women suffering from acute lower uUTIs as measured by the proportion of patients who received an additional antibiotic treatment for acute lower uUTIs during the trial.

Condition or disease Intervention/treatment Phase
Urinary Tract Infection Drug: Canephron® N Drug: Fosfomycin trometamol Drug: Canephron® N-placebo Drug: Fosfomycin trometamol-placebo Phase 3

Detailed Description:

The trial is designed as a comparison of two different modes of action in order to look for alternatives to antibiotic treatment of uncomplicated UTIs. Treatment with CLR is a nonantibiotic therapy and is compared to an antibiotic treatment. Thus, the trial aim is to reduce antibiotics use and moreover to reduce the pressure of developing bacterial resistance against antibiotics due to widespread use, which is an additional advantage of the CLR therapy.

The trial results are expected to demonstrate that antibiotic prescriptions in women for treatment of lower uUTIs can be reduced by an alternative and safe non-antibiotic treatment.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 659 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Controlled, Parallel-group, Randomized, Multicenter Clinical Trial to Assess the Efficacy and Safety of a Herbal Drug Containing Centaury, Lovage Root and Rosemary Leaf (CLR) in Comparison to Fosfomycin Trometamol for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections (uUTIs) in Women
Study Start Date : December 2015
Actual Primary Completion Date : June 2017
Actual Study Completion Date : June 29, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Group Canephron® N
Canephron® N & fosfomycin trometamol-placebo
Drug: Canephron® N
2 tablets 3 times a day for 7 days

Drug: Fosfomycin trometamol-placebo
1 sachet of 8 g of granules; one single dose on Day 1

Active Comparator: Group Fosfomycin Trometamol
Canephron® N-placebo & fosfomycin trometamol
Drug: Fosfomycin trometamol
1 sachet of 8 g of granules; one single dose on Day 1

Drug: Canephron® N-placebo
2 tablets 3 times a day for 7 days




Primary Outcome Measures :
  1. Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4 [ Time Frame: within 38 days after Visit 1 (=day 1) ]

    For patients with consistent or worsening of acute lower uUTI symptoms during the trial the investigator may offer an additional antibiotic therapy at any post-baseline visit. In this case, the patient will be considered a "treatment failure" due to lack of efficacy of the IMP. The alternative antibiotic therapy offered to the patient and the reason for the alternative therapy (i.e., persisting or recurrent symptoms) is to be documented.

    The primary variable for the assessment of efficacy is the proportion of patients who received additional antibiotic treatment for acute lower uUTI between Visit 1 and Visit 4 (defined as AB-rate).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent (IC) and data protection declaration
  2. Female outpatients aged 18 to 70 years
  3. Sum-score of the main uUTI symptoms (dysuria, pollakisuria, and urgency) reported on the Acute Cystitis Symptom Score (ACSS)-"Typical" domain at Visit 1 is ≥6
  4. Symptoms of the acute episode of lower uUTI are developed within not more than 6 days prior to Visit 1
  5. Leukocyturia at Visit 1, confirmed by positive dipstick
  6. Patients willing to refrain from consuming prohibited concomitant medications and products
  7. Non-lactating female patients who are surgically sterile (have had a documented sterilization, bilateral oophorectomy at least 3 months before the start of the trial and/or hysterectomy), or postmenopausal (cessation of menses for at least 12 months), or women of childbearing potential with a negative pregnancy test at Visit 1 willing to use highly effective (failure rate less than 1% per year, i.e., Pearl Index <1) contraception methods, e.g., contraceptive patch, oral, injected or implanted hormonal methods of contraception, during the trial including the follow-up period.

Exclusion Criteria:

  1. Any signs of complicated urinary tract infections (UTIs), pyelonephritis (i.e., fever T ≥38.0°C [grade 2], flank and/or back pain, chills and shivers), and/or vulvo-vaginitis with vaginal and/or with urethral discharge (without urination) at Visit 1.
  2. Any conditions that may lead to complicated infections (i.e., renal diseases, urinary tract abnormalities or past urinary surgery, urine catheterization, uncontrolled diabetes mellitus, spinal cord injury, etc.).
  3. Chronic infection of the urinary tract known from medical history.
  4. Persisting signs or symptoms of severe, progressive, or uncontrolled systemic disease (i.e., renal, hepatic, biliary, hematological, gastro-intestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease).
  5. Uncontrolled hypertension (a diastolic blood pressure >95 mmHg at Visit 1).
  6. Known severe cardiac insufficiency, coronary heart disease, valvular heart disease, cardiac arrhythmia, QT interval prolongation or other severe cardiac disease at Visit 1.
  7. Any antibiotic therapy within 30 days prior to Visit 1.
  8. Other acute infections (except uUTIs) requiring antibiotic treatment at Visit 1.
  9. Patients receiving treatment for suspected or confirmed UTI (antibiotic or phytopharmaceutical) within 30 days prior to Visit 1.
  10. Patients who took anti-inflammatory drugs (e.g., ibuprofen) or spasmolytics for any reason within 24 hours prior to Visit 1, and/or are not willing to stop the intake of any of the medication not permitted for use during the trial.
  11. Known severe impaired renal function (creatinine clearance <20 mL/min).
  12. Active peptic ulcers.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02639520


Locations
Germany
Justus-Liebig-Universität
Giessen, Hessen, Germany, 35392
Sponsors and Collaborators
Bionorica SE
Investigators
Principal Investigator: Florian Wagenlehner, Prof. Universitätsklinikum Gießen und Marburg GmbH

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Bionorica SE
ClinicalTrials.gov Identifier: NCT02639520     History of Changes
Other Study ID Numbers: CanUTI-7
First Posted: December 24, 2015    Key Record Dates
Last Update Posted: July 28, 2017
Last Verified: July 2017

Keywords provided by Bionorica SE:
Uncomplicated urinary tract infection

Additional relevant MeSH terms:
Infection
Urinary Tract Infections
Urologic Diseases
Fosfomycin
Anti-Bacterial Agents
Anti-Infective Agents